IDEXX Laboratories stock (US45168D1046): IDXX edges higher after Monday's close

IDEXX Laboratories shares finished Monday's session at $566.79, up 0.578%, with the Nasdaq-listed stock drawing fresh technical attention in the United States. The move comes as traders monitor the veterinary diagnostics group ahead of its next earnings date and broader U.S. market signals.

IDEXX Laboratories shares ended Monday at $566.79, up 0.578% from $563.53, according to a stock-tracking page that cited the last trading day on 06/01/2026. The move keeps the Nasdaq-listed stock in focus in the United States, where investors continue to watch large-cap health-care names on the Nasdaq and broader U.S. market screens.

The latest session was also flagged by an algorithmic market note that showed current price signals centered on $566.79 and highlighted a near-term bullish sentiment framework for IDXX on 06/01/2026. For readers tracking the U.S. listing, the stock remains traded in USD on Nasdaq under the ticker IDXX, and no positive evidence in the available sources indicates a delisting or take-private process has been completed.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: IDEXX Laboratories
• Sector/industry: Veterinary diagnostics and animal health technology
• Headquarters/country: Westbrook, Maine, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Consumable tests, instruments, software, and recurring diagnostics services for veterinary practices
• Home exchange/listing venue: Nasdaq (IDXX)
• Trading currency: USD

IDEXX Laboratories: core business model

IDEXX Laboratories develops diagnostics, software, and laboratory services for veterinary practices, with recurring demand tied to animal health testing and workflow tools. Its revenue base is driven by consumables, instruments, and reference laboratory services rather than one-off product sales alone.

Latest quarterly results for IDEXX Laboratories at a glance

The company reported first-quarter 2026 results on 05/01/2026, giving investors a recent baseline for revenue and earnings trends before the current trading session. In that release, IDEXX said quarterly revenue reached $998.4 million, compared with $954.6 million a year earlier, while diluted EPS was $2.96 versus $2.81 in Q1 2025, according to the company's investor relations announcement on 05/01/2026.

That same release also said management raised its 2026 outlook, including revenue guidance of $4.21 billion to $4.28 billion and diluted EPS guidance of $12.76 to $13.26, compared with prior guidance of $4.18 billion to $4.26 billion and $12.45 to $12.90. The company has not published a new quarterly update in the sources reviewed for this article, so the May 2026 filing remains the latest primary financial reference point.

Conclusion

Monday's modest gain keeps IDEXX Laboratories in view after a recent earnings update that lifted both revenue and full-year guidance on 05/01/2026. The quarterly backdrop matters because the Tuesday earnings module points to a business still being judged on recurring diagnostics demand, margin execution, and the durability of its 2026 outlook.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.